Allogeneic stem cell transplantation from unrelated donor for class 3 β-thalassemia major using reduced-intensity conditioning regimen [2]

Bone Marrow Transplantation

Volumn 37, Issue 1, 2006, Pages 111-112

  Zhu, K E ^a   Gu, J ^a   Zhang, T ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFEROXAMINE; FERRITIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA; BLOOD TRANSFUSION; CASE REPORT; CHELATION THERAPY; DONOR; FEMALE; FERRITIN BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON OVERLOAD; LETTER; LIVER BIOPSY; LIVER FIBROSIS; LUNG INFECTION; MALE; MOUTH ULCER; PHLEBOTOMY; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SCORING SYSTEM; THALASSEMIA MAJOR;

BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LIVING DONORS; MALE; MYELOABLATIVE AGONISTS; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 31344478517     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705205     Document Type: Letter

References (4)

1. Lucarelli G, Clift RA, Galimberti M, Polchi P, Angelucci E, Baronciani D et al. Marrow transplantation for patients with thalassemia. Results in class 3 patients. Blood 1996; 87: 2082-2088.
2. Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005; 35: 345-352.
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the the treatment of malignant and nonmalignant hematopoietic diseases. Blood 1998; 91: 756-763.
4. Hongeng S, Chuansumrit A, Hathirat P, Rerkamnuaychoke B, Chaisiripoomkere W, Jootar S. Full chimerism in nonmyeloablative stem cell transplantation in a β-thalassemia major patient (class 3 Lucarelli). Bone Marrow Transplant 2002; 30: 409-410.